|
1
|
Narod SA and Foulkes WD: BRCA1 and BRCA2:
1994 and beyond. Nat Rev Cancer. 4:665–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hu YF and Li R: JunB potentiates function
of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated
interaction. Genes Dev. 16:1509–1517. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Solyom S, Aressy B, Pylkäs K, et al:
Breast cancer-associated abraxas mutation disrupts nuclear
localization and DNA damage response functions. Sci Transl Med.
4:122–123. 2012.PubMed/NCBI
|
|
4
|
Wang B, Matsuoka S, Ballif BA, et al:
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA
damage response. Science. 316:1194–1198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Simons AM, Horwitz AA, Starita LM, et al:
BRCA1 DNA-binding activity is stimulated by BARD1. Cancer Res.
66:2012–2018. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi M, Ab E, Bonvin AM and Siegal G:
Structure of the DNA-bound BRCA1 C-terminal region from human
replication factor C p140 and model of the protein-DNA complex. J
Biol Chem. 285:10087–10097. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elstrodt F, Hollestelle A, Nagel JH, et
al: BRCA1 mutation analysis of 41 human breast cancer cell lines
reveals three new deleterious mutants. Cancer Res. 66:41–45. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCarthy A, Savage K, Gabriel A, Naceur C,
Reis-Filho JS and Ashworth A: A mouse model of basal-like breast
carcinoma with metaplastic elements. J Pathol. 211:389–398. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Foulkes WD, Metcalfe K, Sun P, et al:
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer:
The influence of age, grade, and histological type. Clin Cancer
Res. 10:2029–2034. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tung N, Wang Y, Collins LC, et al:
Estrogen receptor positive breast cancers in BRCA1 mutation
carriers: Clinical risk factors and pathologic features. Breast
Cancer Res. 12:R122010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim E, Vaillant F, Wu D, et al: Aberrant
luminal progenitors as the candidate target population for basal
tumor development in BRCA1 mutation carriers. Nat Med. 15:907–913.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poole AJ, Li Y, Kim Y, Lin SC, Lee WH and
Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice
by a progesterone antagonist. Science. 314:1467–1470. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu S, Ginestier C, Charafe-Jauffret E, et
al: BRCA1 regulates human mammary stem/progenitor cell fate. Proc
Natl Acad Sci USA. 105:1680–1685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ginestier C, Liu S and Wicha MS: Getting
to the root of BRCA1-deficient breast cancer. Cell Stem Cell.
5:229–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaplan JS, Schnitt SJ, Collins LC, et al:
Pathologic features and immunophenotype of estrogen
receptor-positive breast cancers in BRCA1 mutation carriers. Am J
Surg Pathol. 36:1483–1488. 2012. View Article : Google Scholar : PubMed/NCBI
|
